At least a third of all ErbB2-positive breast cancers are also ER-positive, and because this breast cancer subgroup appears more refractory to all forms of endocrine therapy [27], it has attracted considerable attention among basic and clinical breast cancer investigators. This evidence concerns the gene ESR1 and breast carcinoma.